These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 39070179)

  • 21. The Analysis of Key Factors Related to ADCs Structural Design.
    Tang H; Liu Y; Yu Z; Sun M; Lin L; Liu W; Han Q; Wei M; Jin Y
    Front Pharmacol; 2019; 10():373. PubMed ID: 31068807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer.
    Park JC; Shin D
    JCO Precis Oncol; 2024 Aug; 8():e2400179. PubMed ID: 39151109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
    Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
    Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer.
    Koukoutzeli C; Trapani D; Ascione L; Kotteas E; Marra A; Criscitiello C; Curigliano G
    Clin Med Insights Oncol; 2024; 18():11795549241260418. PubMed ID: 38894701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers.
    Esapa B; Jiang J; Cheung A; Chenoweth A; Thurston DE; Karagiannis SN
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response.
    Chang HL; Schwettmann B; McArthur HL; Chan IS
    J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37712425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction to Antibody-Drug Conjugates.
    Pettinato MC
    Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stepping forward in antibody-drug conjugate development.
    Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
    Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
    Sheyi R; de la Torre BG; Albericio F
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
    Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
    Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update.
    Dias E Silva D; Andriatte GM; Pestana RC
    Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Antibody Drug Conjugates for Lymphoma.
    Russler-Germain DA; Kahl BS
    Oncology (Williston Park); 2020 Dec; 34(12):522-534. PubMed ID: 33395492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
    Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
    J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.